Co-administration of efavirenz with atazanavir in combination with low-dose ritonavir resulted in substantial decreases in atazanavir exposure due to CYP3A4 induction, necessitating dosage adjustment of atazanavir (refer to the Summary of Product Characteristics for the medicinal product containing atazanavir).